ClinConnect ClinConnect Logo
Search / Trial NCT01979471

The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH

Launched by UNIVERSITY OF ALBERTA · Nov 1, 2013

Trial Information

Current as of May 12, 2025

Completed

Keywords

Cardiovascular Risk Reduction Diabetes Chronic Kidney Disease Atherosclerotic Vascular Disease Community Pharmacist Randomized Controlled Trial [E Gfr <60 Ml/Min/1.73m2 And/Or (Acr >= 30 Mg/Mmol Or Two Consecutive Acr Tests Which Are >= 3 Mg/Mmol)]

ClinConnect Summary

Cardiovascular disease (CVD) is the leading cause of death worldwide accounting for nearly one third of the total deaths. The majority (90%) of the CVD cases are caused by modifiable risk factors. These factors include tobacco smoking, hypertension, hyperlipidemia, diabetes, physical inactivity, high fat diet and obesity.

In Canada CVD rates have decreased drastically over the last few decades, yet it is still one of the leading causes of death. It also carries a financial burden on the Canadian economy with a cost close to $ 21 billion every year divided between loss of productivity and h...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Adults (≥18 years of age) at high risk for cardiovascular events, including:
  • Patients with diabetes
  • Patients with chronic kidney disease \[eGFR \<60 ml/min/1.73m2 and/or (ACR \>= 30 mg/mmol or two consecutive ACR tests which are \>= 3 mg/mmol)\]
  • Patients with established atherosclerotic vascular disease including cerebrovascular disease (prior stroke or transient ischemic attack), cardiovascular disease (myocardial infarction, acute coronary syndrome, stable angina, or revascularization), or peripheral arterial disease (symptomatic and/or ankle brachial index \<0.9).
  • Primary prevention patients with multiple risk factors and Framingham risk score \>20%
  • In order to qualify for inclusion, all patients must have at least one uncontrolled risk factor (i.e., blood pressure, LDL-cholesterol, HbA1c, or current smoking)
  • Exclusion Criteria:
  • Unwilling to participate/sign consent form
  • Unwilling or unable to participate in regular follow-up visits
  • Pregnancy

About University Of Alberta

The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.

Locations

Edmonton, Alberta, Canada

Patients applied

0 patients applied

Trial Officials

Charlotte A Jones, MD, PhD

Principal Investigator

University of British Columbia - Southern Medical Program

Brenda Hemmelgarn, MD, PhD

Principal Investigator

Department of Medicine, University of Calgary

Ross T Tsuyuki, PharmD, MSc

Principal Investigator

Department of Medicine, University of Alberta

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials